A Study to Evaluate BMS-986470
Phase 1/2
184
about 3.3 years
18+
13 sites in AL, CA, CT +6
About this study
This trial is testing a treatment called BMS-986470 in people with healthy volunteers and sickle cell disease. The goal is to see if this treatment is safe, how it works in the body, and if it has any effect on pH levels or food intake.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take BMS-986470
- 2.Take Famotidine
- 3.Take Placebo
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
famotidine
oral (Oral Tablet)
Primary: Number of deaths, Number of participants with AEs leading to discontinuation, Number of participants with AEs meeting protocol-defined Dose Limiting Toxicity (DLT) criteria, Number of participants with adverse events (AEs), Number of participants with serious adverse events (SAEs)
Secondary: Area under the concentration-time curve (AUC), Change from baseline in markers of RBC lysis: absolute reticulocyte count, Change from baseline in markers of RBC lysis: aspartate aminotransferase (AST), Change from baseline in markers of RBC lysis: haptoglobin, Change from baseline in markers of RBC lysis: indirect bilirubin, Change from baseline in markers of RBC lysis: lactate dehydrogenase (LDH), Change from baseline in markers of RBC lysis: reticulocyte percentage of RBCs, Change from baseline in markers of RBC lysis: total bilirubin